PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.85%. A quarter ago, it was expected that this company would post a loss of $0.55 per share when it actually produced a loss of $0.51, delivering a surprise of 7.27%. Over the last four quarters, the comp ...

PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance SAN JOSE, Calif., August 1, 2024 -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights • Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% com ...

SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023 U.S. handpiece and consumables revenue of $27.3 million for the se ...

SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023 U.S. handpiece and consumables revenue of $27.3 million for the se ...

Investors interested in listening to the conference call may do so by following one of the below links: Dial-in registration for sell-side research analysts: https://register.vevent.com/register/BI7bf6aa315a2b44d6a070a16b6608b822 An archived recording will be available on the "Investors" section of the Company's website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event. PROCEPT BioRobotics is a surgical robotics company focused on advancin ...

Company Update - PROCEPT BioRobotics announced that the American Medical Association (AMA) has established a new Current Procedural Terminology (CPT) Category I code for Aquablation therapy, a treatment for benign prostatic hyperplasia (BPH) [1] - The new Category I code will replace the existing Category III code starting January 1, 2026, with hospitals and physicians continuing to use the Category III code (0421T) until then [7] Product and Technology - Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for BPH, offering personalized treatment planning and precise tissue removal while preserving key anatomical functions [2] - The AquaBeam Robotic System, developed by PROCEPT BioRobotics, is an advanced, image-guided surgical robotic system designed for minimally invasive urologic surgery, specifically targeting BPH [4] Market and Clinical Evidence - BPH affects approximately 40 million men in the United States, making it the most common prostate disease [4] - PROCEPT BioRobotics has developed a significant body of clinical evidence, including nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy [4] Leadership and Industry Support - Reza Zadno, CEO of PROCEPT BioRobotics, expressed appreciation for the support and guidance provided by the American Urological Association during the CPT code approval process [2]

SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recording, will be ...

Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION | Delaware | | | 26-0199180 | | --- ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Matt Basco - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Matthew O'Brien - Piper Sandler Josh Jennings - TD Cowen Richard Newitter - Truist. Brandon Vasquez - William Blair Chris Pasquale - Nephron Research Nathan Treybeck ...

PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance SAN JOSE, Calif., May 1, 2024 -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Recent Highlights Net loss was $26.0 million for the first quarter of 2024, compared to a loss of $28.5 million in the ...